1. Home
  2. TOP vs GBIO Comparison

TOP vs GBIO Comparison

Compare TOP & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TOP Financial Group Limited

TOP

TOP Financial Group Limited

HOLD

Current Price

$1.05

Market Cap

43.0M

Sector

Finance

ML Signal

HOLD

Logo Generation Bio Co.

GBIO

Generation Bio Co.

HOLD

Current Price

$5.41

Market Cap

36.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TOP
GBIO
Founded
2015
2016
Country
Singapore
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
43.0M
36.3M
IPO Year
2022
2020

Fundamental Metrics

Financial Performance
Metric
TOP
GBIO
Price
$1.05
$5.41
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$8.88
AVG Volume (30 Days)
48.3K
61.5K
Earning Date
01-26-2026
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,329,256.00
$15,270,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.94
$3.00
52 Week High
$3.33
$12.50

Technical Indicators

Market Signals
Indicator
TOP
GBIO
Relative Strength Index (RSI) 41.34 55.34
Support Level $1.07 $5.20
Resistance Level $1.17 $5.54
Average True Range (ATR) 0.06 0.24
MACD -0.00 0.04
Stochastic Oscillator 38.13 79.66

Price Performance

Historical Comparison
TOP
GBIO

About TOP TOP Financial Group Limited

TOP Financial Group Ltd is an online brokerage firm in Hong Kong specializing in trading local and overseas equities, futures, and options products. The Company generates brokerage commission income by enabling its customers to trade on multiple exchanges present globally. The company operates in only one segment which is the futures brokerage service.

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

Share on Social Networks: